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Abstract: Importance: Clinical outcomes for glioblastoma remain poor. Treatment with immune check-
point blockade has shown benefits in many cancer types. To our knowledge, data from a randomized
phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy for glioblastoma have
not been reported. Objective: To determine whether single-agent PD-1 blockade with nivolumab im-
proves survival in patients with recurrent glioblastoma compared with bevacizumab. Design, Setting,
and Participants: In this open-label, randomized, phase 3 clinical trial, 439 patients with glioblastoma
at first recurrence following standard radiation and temozolomide therapy were enrolled, and 369 were
randomized. Patients were enrolled between September 2014 and May 2015. The median follow-up
was 9.5 months at data cutoff of January 20, 2017. The study included 57 multicenter, multinational
clinical sites. Interventions: Patients were randomized 1:1 to nivolumab 3 mg/kg or bevacizumab 10
mg/kg every 2 weeks until confirmed disease progression, unacceptable toxic effects, or death. Main
Outcomes and Measures: The primary end point was overall survival (OS). Results: A total of 369 pa-
tients were randomized to nivolumab (n = 184) or bevacizumab (n = 185). The MGMT promoter was
methylated in 23.4% (43/184; nivolumab) and 22.7% (42/185; bevacizumab), unmethylated in 32.1%
(59/184; nivolumab) and 36.2% (67/185; bevacizumab), and not reported in remaining patients. At me-
dian follow-up of 9.5 months, median OS (mOS) was comparable between groups: nivolumab, 9.8 months
(95% CI, 8.2-11.8); bevacizumab, 10.0 months (95% CI, 9.0-11.8); HR, 1.04 (95% CI, 0.83-1.30); P = .76.
The 12-month OS was 42% in both groups. The objective response rate was higher with bevacizumab
(23.1%; 95% CI, 16.7%-30.5%) vs nivolumab (7.8%; 95% CI, 4.1%-13.3%). Grade 3/4 treatment-related
adverse events (TRAEs) were similar between groups (nivolumab, 33/182 [18.1%]; bevacizumab, 25/165
[15.2%]), with no unexpected neurological TRAEs or deaths due to TRAEs. Conclusions and Relevance:
Although the primary end point was not met in this randomized clinical trial, mOS was comparable
between nivolumab and bevacizumab in the overall patient population with recurrent glioblastoma. The
safety profile of nivolumab in patients with glioblastoma was consistent with that in other tumor types.
Trial Registration: ClinicalTrials.gov Identifier: NCT02017717.
DOI: https://doi.org/10.1001/jamaoncol.2020.1024
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IMPORTANCE Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from
a randomized phase 3 clinical trial evaluating a programmed death-1 (PD-1) inhibitor therapy
for glioblastoma have not been reported.
OBJECTIVE To determine whether single-agent PD-1 blockade with nivolumab improves
survival in patients with recurrent glioblastoma compared with bevacizumab.
DESIGN, SETTING, AND PARTICIPANTS In this open-label, randomized, phase 3 clinical trial, 439
patients with glioblastoma at first recurrence following standard radiation and temozolomide
therapy were enrolled, and 369were randomized. Patients were enrolled between
September 2014 andMay 2015. Themedian follow-up was 9.5 months at data cutoff of
January 20, 2017. The study included 57multicenter, multinational clinical sites.
INTERVENTIONS Patients were randomized 1:1 to nivolumab 3mg/kg or bevacizumab 10
mg/kg every 2 weeks until confirmed disease progression, unacceptable toxic effects, or
death.
MAIN OUTCOMES ANDMEASURES The primary end point was overall survival (OS).
RESULTS A total of 369 patients were randomized to nivolumab (n = 184) or bevacizumab
(n = 185). TheMGMT promoter was methylated in 23.4% (43/184; nivolumab) and 22.7%
(42/185; bevacizumab), unmethylated in 32.1% (59/184; nivolumab) and 36.2% (67/185;
bevacizumab), and not reported in remaining patients. At median follow-up of 9.5 months,
median OS (mOS) was comparable between groups: nivolumab, 9.8months (95% CI,
8.2-11.8); bevacizumab, 10.0months (95% CI, 9.0-11.8); HR, 1.04 (95% CI, 0.83-1.30); P = .76.
The 12-month OS was 42% in both groups. The objective response rate was higher with
bevacizumab (23.1%; 95% CI, 16.7%-30.5%) vs nivolumab (7.8%; 95% CI, 4.1%-13.3%). Grade
3/4 treatment-related adverse events (TRAEs) were similar between groups (nivolumab,
33/182 [18.1%]; bevacizumab, 25/165 [15.2%]), with no unexpected neurological TRAEs or
deaths due to TRAEs.
CONCLUSIONS AND RELEVANCE Although the primary end point was notmet in this
randomized clinical trial, mOSwas comparable between nivolumab and bevacizumab in the
overall patient population with recurrent glioblastoma. The safety profile of nivolumab in
patients with glioblastomawas consistent with that in other tumor types.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02017717
JAMA Oncol. 2020;6(7):1003-1010. doi:10.1001/jamaoncol.2020.1024
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G
lioblastoma has a poor prognosis, with a 5-year sur-
vival rate of less than 10%.1,2Nearly all patients expe-
rience recurrence following standard-of-care surgical
resection, radiotherapy, and temozolomide.2-4Treatment op-
tions at recurrence are limited, and no therapy has prolonged
overall survival (OS) in this setting,whichunderscores theneed
fornovel therapeutic interventions in thispatientpopulation.4
Useof immunotherapy topromote antitumor immune re-
sponse is an area of active research in the treatment of glio-
blastoma.Accumulating evidence suggests that immune cells
are able to enter, proliferate, and function in the central ner-
vous system(CNS), and residentmacrophagescanexpressma-
jor histocompatibility complex II antigens andT-cell costimu-
latory cytokines on activation.5 These data and results from
murinegliomamodels showing improvedsurvivalwithcheck-
point inhibitors6 suggest that immune checkpoint blockade
may be a potential treatment option for glioblastoma.
Nivolumab is a fully human immunoglobulin G4 mono-
clonal antibody targeting the programmed death-1 (PD-1) im-
mune checkpoint receptor. The safety of nivolumab in recur-
rent glioblastoma was demonstrated in the phase 1 safety
lead-in cohorts of theCheckMate 143 randomized clinical trial
(NCT02017717).7 On the basis of these safety results,7 a
randomized, open-label, phase 3 cohort was initiated to
compare theefficacy andsafetyofnivolumabvsbevacizumab
in patients with first recurrence of glioblastoma.
Methods
Study Design and Patients
The trial protocol is available in Supplement 1, and the statisti-
cal analysis plan is included in Supplement 2. Cohort 2 of the
CheckMate 143 trialwasa randomized,open-label, phase3 trial
conductedat57clinicalsites in12countries.Eligiblepatientshad
histologicallyconfirmedWorldHealthOrganizationgrade IVre-
current glioblastoma or gliosarcoma (as defined by Response
Assessment in Neuro-Oncology criteria8) after first-line treat-
ment with radiotherapy and temozolomide, were 18 years or
older, had a Karnofsky performance status of 70 or higher, and
were28daysor longer fromprior surgeryand 12weeksormore
from prior radiation. Patients who hadmore than 1 recurrence
of glioblastoma, had a diagnosis of secondary glioblastoma, or
required escalating or chronic supraphysiological doses of cor-




rollment was increased by 120 patients to compensate for pa-
tient voluntarywithdrawal in the bevacizumab arm.
The study protocol was approved by the institutional re-
view board or independent ethics committee of each partici-
pating institution.Thestudywasconducted inaccordancewith
the Declaration of Helsinki and Good Clinical Practice, as de-
fined by the International Conference on Harmonisation. All
patients provided written informed consent prior to enroll-
ment. Randomization andmaskingmethods are described in
the eMethods in Supplement 3.
Study Procedures
Patients received 3 mg/kg of nivolumab or 10 mg/kg of beva-
cizumab intravenously every 2 weeks. Study treatment con-
tinued until investigator-assessed progressive disease or on-
set of toxic effects requiring permanent discontinuation of
study treatment. Patients could continue study treatment fol-
lowing first evidence of progression until confirmed by
follow-upmagnetic resonance imaging (MRI)within 12weeks
if therewas evidence of investigator-assessed clinical benefit
and adequate tolerability.
Tumor assessments were performed by the investigator
using contrast-enhancedMRI at baseline, day 1 ofweeks 7 and
13, and every 8 weeks thereafter.8 Follow-up for survival oc-
curred every 3 months. Adverse events (AEs) were assessed
continuously during treatment and for 100days ormore after
the end of treatment according to National Cancer Institute
CommonTerminologyCriteria forAdverseEvents (version4.0).
At the time of enrollment, data onMGMT promotermethyla-
tion status (as locally assessed) were collected without infor-
mationonmethodof assessment; testingwasnot required for
enrollment. PD-L1 testing methods are described in the
eMethods in Supplement 3.
Outcomes
The primary end point was OS, defined as the time from ran-
domization to death from any cause, assessed for each group
using the Kaplan-Meier method. Secondary end points were
OS rate at 12 months, investigator-assessed progression-free
survival (PFS; defined as time from randomization to disease
progression or death from any cause), and investigator-
assessed objective response rate (ORR; defined as confirmed
complete response [CR] or partial response [PR]). Explor-
atory end points included safety and OS in prespecified pa-
tient subgroups, includingMGMT promotermethylation sta-
tus (methylatedvsunmethylated) andbaseline corticosteroid
use (yes [within 5 days of first dose] vs no). Because cortico-
steroids suppress the immune response,9 additional analy-
ses were performed to explore whether no baseline cortico-
steroid use had a survival benefit based on patients’ MGMT
promoter methylation status.
Key Points
Question Does programmed cell death 1 immune checkpoint
inhibition with nivolumab improve overall survival compared with
bevacizumab treatment for patients with recurrent glioblastoma?
Findings In this randomized phase 3 clinical trial of 369 patients
diagnosed with recurrent glioblastoma treated with nivolumab, an
improved survival benefit was not observed in patients who
received nivolumab compared with bevacizumab-treated control
patients.
Meaning Additional research is needed; nivolumabmonotherapy
did not improve overall survival compared with bevacizumab in
the treatment of recurrent glioblastoma. A study of nivolumab in
combination with radiotherapy and temozolomide in patients with
newly diagnosed glioblastomawith methylatedMGMT promoter is
ongoing.
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Statistical Analysis
The final analysis of OS was planned for when 300 or more
deaths were reported among 369 randomized patients, pro-
viding approximately 92% power with an overall type I error
of 0.05. Overall survival was compared between treatment
groups using a 2-sided log-rank test stratified by the pres-
ence or absence of measurable disease at baseline. Kaplan-
Meier methodology was used to estimate survival in each
group, including medians (95% CI) and OS rates, and the
hazard ratios (HRs [95% CIs]) were estimated using a Cox
proportional hazards model adjusted for measurable dis-
ease. Additional statistical methods are described in the
eMethods in Supplement 3. The software used for statistical
analyses was SAS statistical software (version 9.2; SAS Insti-




From September 2014 through May 2015, 369 patients were
randomized to nivolumab (n = 184) or bevacizumab (n = 185)
(Figure 1). Demographics and baseline clinical characteristics
were relatively well balanced between treatment groups. Pa-
tients in the nivolumab group had a numerically longer me-
dian time interval from diagnosis to recurrence (10.1 months
[range,3.4-49.6months]vs8.5months [range,0-38.2months])
(Table 1). No patients used the NovoTTF-100L system during
the study.
Of 369 randomized patients, 347 received study treat-
ment with nivolumab (n = 182 [52.4%]) or bevacizumab
(n = 165 [47.6%]). Final analysis was performed when 301
patients had died. At data cutoff (January 20, 2017), median
(range) follow-up was 9.8 (1.3-26.3) months in the
nivolumab group and 9.4 (0-26.8) months in the bevaci-
zumab group, and 175 of 184 patients (95%) in the
nivolumab group and 158 of 185 patients (85%) in the
bevacizumab group had permanently discontinued study
treatment; the most common reasons were disease progres-
sion (nivolumab, n = 162 [89.0%]; bevacizumab, n = 132
[80.0%]) and study drug-assoc iated toxic effects
(nivolumab, n = 6 [3.3%]; bevacizumab, n = 11 [6.7%])
(Figure 1). Duration of study treatment and number of doses
are described in the eResults in Supplement 3.
Efficacy
No statistical difference was observed in the risk of death
between groups (HR, 1.04; 95% CI, 0.83-1.30; P = .76); 154 of
184 patients (83.7%) in the nivolumab group died vs 147 of
185 patients (79.5%) in the bevacizumab group. Median OS
(mOS) was similar: 9.8 months (95% CI, 8.2-11.8 months)
with nivolumab vs 10.0 months (95% CI, 9.0-11.8 months)
with bevacizumab (HR, 1.04; 95% CI, 0.83-1.30; P = .76)
(Figure 2A). Median PFS was 1.5 months (95% CI, 1.5-1.6
months) with nivolumab and 3.5 months (95% CI, 2.9-4.6
months) with bevacizumab (HR, 1.97; 95% CI, 1.57-2.48;
P < .001) (Figure 2B).
The ORR in patients evaluable for response in the
nivolumab (n = 153) and bevacizumab (n = 156) groups was
7.8% (95% CI, 4.1%-13.3%) and 23.1% (95% CI, 16.7%-30.5%)
(eTable 1 in Supplement 3). Additional ORR data are pre-
sented in the eResults in Supplement 3. Responses were nu-
merically more durable with nivolumab than with bevaci-
zumab,with respective duration-of-responsemedian (range)
of 11.1 (0.6-18.7) months and 5.3 (3.1-24.9) months.
Exploratory Analyses
Overall, OS was generally similar between prespecified pa-
tient subgroups (Figure 3A).Yet, amongpatientswithnobase-
line corticosteroid use, the HR for nivolumab vs bevaci-
zumabwas0.84 (95%CI, 0.62-1.15), and amongpatientswith
baseline corticosteroid use, the HR for nivolumab vs bevaci-
zumabwas 1.41 (95%CI, 1.01-1.97) (Figure 3A). Thedifference
inmOSbetweenpatientswith baseline corticosteroiduse and
those without was thus greater with nivolumab (7.0 vs 12.6
months) than with bevacizumab (8.9 vs 11.8 months) (eFig-
ure 1 in Supplement 3).
ThemOSwas longer in patientswith tumorswith ameth-
ylated MGMT promoter in both treatment groups (eFigure 2
in Supplement 3). There was a trend for inferior mOS with
nivolumab inpatientswithunmethylatedMGMTpromoter tu-
mors (HR, 1.34; 95% CI, 0.92-1.96) but not in patients with
methylated MGMT promoter tumors (HR, 0.92; 95% CI,
Figure 1. Study Profile
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CONSORT diagram showing the number of patients in CheckMate 143 cohort 2
whowere enrolled, treated with nivolumab or bevacizumab, discontinued
treatment, and analyzed for efficacy and safety. Q2W indicates every 2 weeks.
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Table 1. Patient Demographics and Baseline Characteristics
Characteristic
No. (%)
Nivolumab (n = 184) Bevacizumab (n = 185)
Age, median (range), y 55.5 (22-77) 55.0 (22-76)
<65 y 142 (77.2) 156 (84.3)
Male 116 (63.0) 119 (64.3)
Histopathologic diagnosis
Glioblastoma 183 (99.5) 184 (99.5)
Gliosarcoma 1 (0.5) 1 (0.5)
Radiotherapy completed 184 (100.0) 185 (100.0)
Temozolomide received 183 (99.5) 185 (100.0)
Median No. of prior temozolomide cycles (range) 6.0 (0-42) 5.0 (1-26)
Time from last RT dose to first dose of study drug
No. of patients 182 163
Median (range), mo 8.8 (1.8-47.5) 6.9 (1.1-36.9)
Time from initial diagnosis to recurrence
Median (range), mo 10.1 (3.4-49.6) 8.5 (0-38.2)
<1 y 108 (58.6) 139 (75.1)
≥1 y 76 (41.3) 46 (24.9)
Karnofsky performance status at study entry
100 42 (22.8) 25 (13.5)
90 71 (38.6) 78 (42.2)
80 50 (27.2) 57 (30.8)
70 19 (10.3) 24 (13.0)
<70 2 (1.1) 0
Not reported 0 1 (0.5)
Measurable target lesion(s) 153 (83.2) 156 (84.3)
Target lesion size, median (range), mm2 859.0 (100-5278) 854.0 (110-4030)
Site of target lesion(s)
Temporal lobe 64 (34.8) 54 (29.2)
Frontal lobe 49 (26.6) 53 (28.6)
Parietal lobe 23 (12.5) 27 (14.6)
Occipital lobe 12 (6.5) 11 (5.9)
Cerebellum 0 2 (1.1)
Brain stem 1 (0.5) 0
Insula 0 1 (0.5)
Other 20 (10.9) 28 (15.1)
MGMT promoter methylation status
Methylated 43 (23.4) 42 (22.7)
Unmethylated 59 (32.1) 67 (36.2)
Not reported 82 (44.6) 76 (41.1)
PD-L1 expression level
<1% 107 (58.2) 114 (61.6)
≥1% 48 (26.1) 35 (18.9)
Not quantifiable 29 (15.8) 36 (19.5)
Corticosteroid usea
Yes 73 (39.7) 79 (42.7)
<2 mg/d 20 (10.9) 25 (13.5)
≥2 to <4 mg/d 27 (14.7) 26 (14.1)
≥4 mg/d 26 (14.1) 28 (15.1)
No 111 (60.3) 106 (57.3)
Abbreviations: PD-L1, programmed
death ligand 1; RT, radiotherapy.
a Dexamethasone equivalents.
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0.56-1.51) (Figure 3A) (eResults in Supplement 3). Other dis-
ease characteristics, suchasperformance status (Figure 3A) or
size of residual tumor, were not associated with OS.
Hypothesis-generating subgroup analyses were con-
ducted to evaluate OS in prespecified subgroups. In a multi-
variable Cox proportional hazards model analysis, no base-
line corticosteroid use (HR, 0.59; 95% CI, 0.36-0.95) and
methylatedMGMT promoter status (HR, 0.47; 95% CI, 0.29-
0.78) were each associated with longer OS in the nivolumab
group (eTable 2 in Supplement 3). With bevacizumab, meth-
ylatedMGMT promoter status was associated with longer OS
(HR, 0.54; 95%CI, 0.32-0.89) (eTable 2 in Supplement 3), but
no baseline corticosteroid use was not. On the basis of these
results, the combined association of baseline MGMT pro-
motermethylation status and corticosteroid usewith OSwas
evaluated. Among patients with methylated MGMT pro-
moter and no baseline corticosteroid use, a trend toward lon-
ger mOS was observed in nivolumab-treated patients than in
bevacizumab-treated patients (17.0 vs 10.1months; HR, 0.58;
95% CI, 0.30-1.11) (Figure 3, B and C) (eResults in
Supplement 3).
Safety
Any-grade TRAEs occurred at similar rates in the nivolumab
(103/182;56.6%)andbevacizumab(95/165;57.6%)groups,with
the most common being fatigue in the nivolumab group and
hypertension in thebevacizumabgroup (Table2). Similar rates
of grade 3/4 TRAEs were reported with nivolumab (33/182;
18.1%) andbevacizumab (25/165; 15.2%).Neurological TRAEs
were reported in 25 of 182 (13.7%) nivolumab-treated
patients (grade3/4,8 [4.4%])and16of 165 (9.7%)bevacizumab-
treatedpatients (grade 3/4, 2 [1.2%]); no individual neurologi-
cal TRAEs were reported in 5% or more of patients. Serious
TRAEs are described in the eResults in Supplement 3.
Immune-mediated AEs (IMAEs) reported in 2% or more
of patients are shown in eTable 4 in Supplement 3; the most
common were diarrhea (nivolumab, 27 [14.8%]; bevaci-
zumab, 13 [7.9%]), increased alanine aminotransferase (15
[8.2%]; 9 [5.5%], respectively), and rash (17 [9.3%]; 7 [4.2%],
respectively). No treatment-related deaths were reported.
Discussion
TheCheckMate 143 trialwas the first randomizedphase3study




numerically better in thebevacizumabgroup.Durationsof re-
sponsewerenumerically longer in thenivolumabgroup.Toxic
effects were consistent with the known safety profiles of
nivolumab and bevacizumab.10,11No new safety signals were
observed, including no apparent increase in the incidence of
neurological TRAEs.
Hypothesis-generating data from subgroup analyses
indicated that corticosteroid use at baseline, a known prog-
nostic factor for patients with glioblastoma,12 seemed to be
disproportionally and unfavorably associated with out-
comes in the nivolumab group. Patients requiring cortico-
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A, The number of events; median OS; OS rates at 6, 12, and 18months; and the
Kaplan-Meier curve for OS in all patients treated with nivolumab or
bevacizumab. B, The number of events; median PFS; PFS rates at 6, 12, and 18
months; and the Kaplan-Meier curve for PFS per investigator assessment in
patients treated with nivolumab or bevacizumab. Symbols indicate censored
observations. Hazard ratios (HRs) and CIs were estimated using a Cox
proportional hazards model.
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steroids to treat symptomatic cerebral edema may have
more rapidly progressive disease and may not have suffi-
cient time to derive benefit from immunotherapy. Further-
more, direct effects of corticosteroids on T-cell function
might abrogate activation or priming of the immune
system.13
The association of MGMT promoter methylation, a well-
knownprognostic factor forpatientswithglioblastoma,14with


























Unstratified hazard ratios for death in patient subgroupsA
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A, Forest plot of unstratified hazard ratios (HRs) for death in the analysis of
treatment effect in prespecified patient subgroups according to baseline
characteristics. B, Exploratory post hoc analyses of the number of events,
median OS, and Kaplan-Meier curves for OS in prespecified patient subgroups
treated with nivolumab. C, Exploratory post hoc analyses for bevacizumab.
Subgroups include patients with methylated tumors who did not receive
corticosteroids at baseline, patients with methylated tumors who received
corticosteroids at baseline, patients with unmethylated tumors who did not
receive corticosteroids at baseline, and patients with unmethylated tumors who
received corticosteroids at baseline. Symbols indicate censored observations;
HRs and CIs were estimated using a Cox proportional hazards model.
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survival was also analyzed. Longer mOS was observed in pa-
tientswithmethylated tumors than in patientswith unmeth-
ylated tumors inboth treatmentgroups.Thedifference inmOS
between patients with vs without methylated MGMT pro-
moter tumorswasnumerically greater in thenivolumabgroup
than in thebevacizumabgroup. Thepost hoc subgroupanaly-
ses indicated that the subgroup of patientswith glioblastoma
withmethylatedMGMTpromoter andnobaseline corticoste-
roiddependencemaybemost likely toderivebenefit from im-
mune checkpoint inhibition.
Limitations
Study limitations include the small number of patients in
the subgroup analyses, lack of standardized MGMT pro-
moter methylation status assessment, insufficient data on
quality of life assessments, and use of archival tissue col-
lected at the time of initial diagnosis for biomarker analyses.
Conclusions
To our knowledge, the CheckMate 143 randomized clinical
trial is the first phase 3 study investigating the use of a PD-1
inhibitor in patients with recurrent glioblastoma. The study
did not meet the primary end point of OS. The safety profile
of nivolumab in patients with glioblastoma was consistent
with that in other tumor types. Patients with methylated
MGMT promoter glioblastoma and no baseline corticoste-
roid use may potentially derive benefit from treatment with
immune checkpoint inhibition.
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